PHARMExcel to support trial delivery of world-first Covid-19 vaccine booster study.
PHARMExcel is delighted to be announced as the UK Contract Research Organisation (CRO) supporting University Hospital Southampton in the delivery of a world-first Covid-19 vaccine booster study. The Cov-Boost study, backed by £19.3 million of government funding through the Vaccines Taskforce, will be run at University Hospital Southampton, University Hospitals Dorset and the Portsmouth Research…
Sanofo-GSK vaccine showing positive Phase II data
Increasing confidence jabs work against Indian variant
US approves Pfizer COVID-19 vaccine for children aged 12 to 15
New NHS legislation provides ‘once-in-a-decade opportunity’ to centre research
PHARMExcel instrumental in supporting the re-opening of Biotherapy Services DFU trial
Biotherapy Services are very pleased to announce our RAPID-1 (Diabetic Foot Ulcer) trial has enrolled and dosed its first patient following suspension of the trial due to the Covid-19 pandemic restrictions. This could only have been made possible with the collaborative approach from the PHARMExcel team, who took over the trial management in early 2020….
Moderna becomes third Covid vaccine approved in the UK
PHARMExcel announces Silver accreditation for Investors in People
Investors in People Silver accreditation acknowledges that PHARMExcel has been awarded one of the highest levels of accreditation within the Investors in People framework. The Silver accreditation is usually awarded to the top 5% of organisations assessed.